MEDICAMEQ — Medicamen Biotech Share Price
0.000.00%
Last trade - 00:00- IN₹6.88bn
- IN₹7.04bn
- IN₹1.79bn
- 53
- 10
- 47
- 26
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.33 | ||
| Price to Tang. Book | 3.34 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.82 | ||
| EV to EBITDA | 37.6 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 5.51% | ||
| Return on Equity | 4.05% | ||
| Operating Margin | 6.41% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 1,255.04 | 1,127.16 | 1,154.45 | 1,408.67 | 1,793.06 | n/a | n/a | 7.9% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +6.71 | -9.53 | +22.75 | -2.18 | -27.24 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Medicamen Biotech Limited is an India-based integrated pharmaceutical and life sciences solution provider company. The Company is engaged in research and development, manufacturing, marketing, and distribution of pharmaceutical products. The Company manufactures products across various therapeutic categories, including Pain Management, Cough and Cold, Cardiovascular and Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic, among others. The Company manufactures a range of products, including tablets, capsules, dry syrup, non-beta lactum, ointments, and creams. Its oncology products include Abiraterone acetate, Anastrozole, Bicalutamide, Bendmustine HCL, Bortezomib, Busulfan, Capecitabine, Cisplatin, Erlotinib HCL, Gefitinib, Imatinib mesylate, Letrozole, Melphalan, Oxaliplatin, Pazopanib, Its Cardiology products include Nifedipine Capsules, Atorvastatin Tablets, Fenofibrate Capsules, Rosuvastatin Tablets.
Directors
- Rajesh Madan CEO
- Bal Gupta MDR
- Parul Choudhary SEC
- Rahul Bishnoi DRC
- Ashwani Sharma DRC
- Vimal Shrawat DRC (59)
- Suresh Singh DRC (76)
- Ravi Bansal IND (58)
- Sangeeta Bishnoi IND
- Sumita Dwivedi IND
- Harish Pande IND
- Last Annual
- March 31st, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- December 22nd, 1993
- Public Since
- July 27th, 1995
- No. of Employees
- 378
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 12,651,100
- Address
- 1506, Chiranjiv Tower, 43, Nehru Place, NEW DELHI, 110019
- Web
- https://medicamen.com/
- Phone
- +91 1147589500
- Auditors
- Rai Qimat & Associates
Upcoming Events for MEDICAMEQ
Q3 2025 Medicamen Biotech Ltd Earnings Release
Similar to MEDICAMEQ
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Medicamen Biotech share price?
As of Today at 21:58 UTC, shares in Medicamen Biotech are trading at IN₹544.15. This share price information is delayed by 15 minutes.
How has the Medicamen Biotech share price performed this year?
Shares in Medicamen Biotech last closed at IN₹544.15 and the price had moved by -15.6% over the past 365 days. In terms of relative price strength the Medicamen Biotech share price has underperformed the S&P BSE 100 Index by -35.64% over the past year.
What are the analyst and broker recommendations for Medicamen Biotech?
There is no consensus recommendation for this security.
Find out moreWhat is the Medicamen Biotech dividend yield?
The Medicamen Biotech dividend yield is 0.18% based on the trailing twelve month period.
Does Medicamen Biotech pay a dividend?
Last year, Medicamen Biotech paid a total dividend of IN₹1.00, and it currently has a trailing dividend yield of 0.18%. We do not have any data on when Medicamen Biotech is to next pay dividends.
When does Medicamen Biotech next pay dividends?
We do not have data on when Medicamen Biotech is to next pay dividends. The historic dividend yield on Medicamen Biotech shares is currently 0.18%.
How do I buy Medicamen Biotech shares?
To buy shares in Medicamen Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Medicamen Biotech?
As of the previous close price of IN₹544.15, shares in Medicamen Biotech had a market capitalisation of IN₹6.88bn.
Where are Medicamen Biotech shares listed?
Here are the trading details for Medicamen Biotech:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: MEDICAMEQ
What kind of share is Medicamen Biotech?
Based on an overall assessment of its quality, value and momentum Medicamen Biotech is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Medicamen Biotech share price forecast for 2024?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Medicamen Biotech share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medicamen Biotech. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +13.51%.
As of the last closing price of IN₹544.15, shares in Medicamen Biotech were trading +12.64% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Medicamen Biotech PE Ratio?
The Medicamen Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹544.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Medicamen Biotech?
Medicamen Biotech's management team is headed by:
- Rajesh Madan - CEO
- Bal Gupta - MDR
- Parul Choudhary - SEC
- Rahul Bishnoi - DRC
- Ashwani Sharma - DRC
- Vimal Shrawat - DRC
- Suresh Singh - DRC
- Ravi Bansal - IND
- Sangeeta Bishnoi - IND
- Sumita Dwivedi - IND
- Harish Pande - IND